Advertisement

Topics

FDA approves non-radioactive, dual-tracer for sentinel lymph node biopsy

06:59 EDT 2 Aug 2018 | ecancermedicalscience

The U.S. Food and Drug Administration (FDA) has announced pre-market approval for Magtrace, the first non-radioactive, dual-tracer for lymphatic mapping in patients with breast cancer undergoing a mastectomy. Magtrace is a liquid marker designed to...

Original Article: FDA approves non-radioactive, dual-tracer for sentinel lymph node biopsy

NEXT ARTICLE

More From BioPortfolio on "FDA approves non-radioactive, dual-tracer for sentinel lymph node biopsy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...